To date, several clinical trials have been initiated for treating head and neck squamous cell carcinoma (HNSCC) with STING agonists including ADU-S100, SB-11285, and MK-1454 [66,67,68]. This evidence concerns the gene STING1 and head and neck squamous cell carcinoma.